Valuation: Quest PharmaTech Inc.

Market Cap 3.38M 2.41M 2.09M 1.95M 1.79M 229M 3.42M 22.89M 8.99M 115M 9.06M 8.86M 380M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.12M 2.7M 2.52M 2.31M 296M 4.42M 29.56M 11.6M 148M 11.7M 11.45M 491M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer - 16/06/2004
Director of Finance/CFO - 31/12/2004
Director TitleAgeSince
Director/Board Member - 16/06/2004
Chairman - 04/07/2021
Director/Board Member - 04/07/2021
Change 5-day change 1-year change 3-year change Capi.($)
-34.61%+0.12% - - 2.4M
+0.90%+0.21%-0.74%+13.87% 48B
+1.98%+9.05%+413.94%+565.65% 41.13B
+3.44%-4.65%+28.34%+7.64% 37.56B
+1.40%+0.10%+6.61%+74.66% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
-0.16%-3.11% - - 16.12B
+2.20%+0.48%+34.71%+125.72% 16.05B
+1.25%+1.69%+4.72%+18.26% 13.76B
+4.25%-8.23%-1.49%-35.00% 12.1B
Average -1.75%-2.15%+62.62%+101.95% 27.83B
Weighted average by Cap. +1.80%-1.29%+82.52%+128.35%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.28M -1.11M -1.04M -954K -122M -1.82M -12.19M -4.78M -61.13M -4.83M -4.72M -202M 5M 3.57M 3.09M 2.88M 2.65M 339M 5.05M 33.83M 13.28M 170M 13.39M 13.1M 562M
Net Debt 795K 567K 491K 458K 421K 53.92M 804K 5.38M 2.11M 26.98M 2.13M 2.08M 89.35M 986K 703K 609K 568K 522K 66.86M 997K 6.67M 2.62M 33.45M 2.64M 2.58M 111M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-